Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | FLT3 positive |
Gene Variant Detail | |
Relevant Treatment Approaches |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06325748 | Phase I | SENTI-202 | SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS | Recruiting | USA | AUS | 0 |
NCT02846376 | Phase I | Ipilimumab Ipilimumab + Nivolumab Nivolumab | Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002) | Terminated | USA | 0 |
NCT03904069 | Phase I | Anti-FLT3 CAR-T cells | Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML | Withdrawn | USA | 0 |